Succinity Produces First Commercial Quantities of Bio-Based Succinic Acid
Succinity GmbH, the joint venture between Corbion Purac and BASF for the production and commercialization of bio-based succinic acid, has announced the successful start-up of its first commercial production facility. The plant, located at the Corbion Purac site in Montmeló, Spain, has an annual capacity of 10,000 metric tons and is producing commercial quantities of bio-based succinic acid for the global market. In addition to this first facility, Succinity plans a second large-scale facility. The final investment decision for this facility will be made following a successful market introduction.
“The start-up of our first facility for Succinity bio-based succinic acid represents a key milestone in our plan to become a major producer of biobased succinic acid in the future,” comments Philipp Walter, Managing Director of Succinity. “The combined experiences of the team in Montmeló and the support from Corbion Purac and BASF have ensured the achievement of this important milestone within schedule. With the facility in Spain we will be able to serve the growing succinic acid market.”
The Succinity process is based on renewable raw materials and fixes carbon dioxide. The proprietary micro-organism Basfia succiniciproducens allows for a flexible usage of different feedstocks. Furthermore, Succinity bio-based succinic acid can be produced efficiently without major waste streams thanks to a closed-loop process. An elaborate downstream processing method ensures the production of high quality biobased succinic acid.
Based on technological advances and an increased need for renewable intermediates in different application fields, BASF and Corbion Purac have been working on the development of bio-based succinic acid since 2009. Bio-based succinic acid features a significantly improved carbon footprint compared to conventional, fossil-based succinic acid or other dicarboxylic acids. Bio-based succinic acid is a versatile building block with a significant market potential in the chemical intermediates market. It can be used in a variety of potential applications, such as bio-polymers (e.g. Polybutylene succinate, PBS), polyurethanes, coatings and life science products.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance